Subsidiaries & Affiliates
At Bukwang, our unique network of subsidiaries, joint-venture affiliates,
collaborative partnerships, and investee alliances empowers us to
embark on a diverse array of initiatives aimed at bolstering our pipeline,
securing development and marketing rights, discovering and developing
new drug candidates, and catalyzing the growth of innovative ventures.
-
CONTERA PHARMA A/S
Founded in 2010, Contera Pharma is a Denmark-based biotechnology company specializing in central nervous system (CNS) disorders, co-founded by former researchers from Novo Nordisk and Novartis. Currently, the company is driving innovative R&D focused on RNA-based therapeutics, alongside its lead program 'CP-012', a treatment for morning akinesia in Parkinson's disease. Bukwang Pharmaceutical acquired Contera Pharma as a subsidiary in November 2014 and holds a 100% stake as of 2026.
-
BUKWANG MEDICA
Founded in June 2015, Bukwang Medica is a wholly owned subsidiary that
handles the sales and distribution of our growing nutraceutical product
lineup under the Bukwang Lab brand.
-
JAGUAHR THERAPETICS
JaguAhR is a Singapore-based joint venture with Aslan Pharmaceuticals focused
on developing novel immuno-oncology therapeutics targeting the aryl
hydrocarbon receptor (AhR) pathway. We hold a 75% equity stake in the biotech.